ReviewInternational journal of molecular sciences2021
Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Probiotic and paraprobiotic intervention modulates testicular DNA methylation in streptozotocin-induced diabetic rats: insights into the role of Lactobacillus rhamnosus GG.Scientific reports · 2026Article
- Diabetes and its complications: molecular mechanisms, prevention and treatment.Signal transduction and targeted therapy · 2026Review
- Childhood type 1 diabetes mellitus and gut microbiota: from microbiome characteristics to prevention and treatment strategies.Frontiers in cellular and infection microbiology · 2026Review
- Unveiling the gut connection: Exploring the link between microbiota and type 1 diabetes onset in pediatric patients.Biomedical reports · 2026Article
- Diabetic gastrointestinal autonomic neuropathy: Integrating neuronal degeneration and gut microbial dysbiosis.World journal of diabetes · 2025Review
- Evaluating the Efficacy of Secondary Metabolites in Antibiotic-Induced Dysbiosis: A Narrative Review of Preclinical Studies.Antibiotics (Basel, Switzerland) · 2025Review
- Assessment of ImmobilizedFoods (Basel, Switzerland) · 2024Article
- Diabetic neuropathy: understanding the nexus of diabetic neuropathy, gut dysbiosis and cognitive impairment.Journal of diabetes and metabolic disorders · 2024Review
- Effects of Free or ImmobilizedMicroorganisms · 2024Article
- Metabolic Syndrome and Biotherapeutic Activity of Dairy (Cow and Buffalo) Milk Proteins and Peptides: Fast Food-Induced Obesity Perspective-A Narrative Review.Biomolecules · 2024Review
- Exploring the severity and early onset of familial type 1 diabetes in Romania: genetic and microbiota insights.Archive of clinical cases · 2024Article
- Nutritional Interventions withInternational journal of molecular sciences · 2023Article
- Article
- Study of the gut microbiome in Egyptian patients with type 1 diabetes mellitus.Przeglad gastroenterologiczny · 2023Article
- Phylogenetic Diversity of Animal Oral and Gastrointestinal Viromes Useful in Surveillance of Zoonoses.Microorganisms · 2022Review
- Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2022Review
- Gut microbiota diversity in middle-aged and elderly patients with end-stage diabetic kidney disease.Annals of translational medicine · 2022Article
- Review
- Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes mellitus.Frontiers in immunology · 2022Article
- Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Globally, we are facing a worrying increase in type 1 diabetes mellitus (T1DM) incidence, with onset at younger age shedding light on the need to better understand the mechanisms of disease and step-up prevention. Given its implication in immune system development and regulation of metabolism, there is no surprise that the gut microbiota is a possible culprit behind T1DM pathogenesis. Additionally, microbiota manipulation by probiotics, prebiotics, dietary factors and microbiota transplantation can all modulate early host-microbiota interactions by enabling beneficial microbes with protective potential for individuals with T1DM or at high risk of developing T1DM. In this review, we discuss the challenges and perspectives of translating microbiome data into clinical practice. Nevertheless, this progress will only be possible if we focus our interest on developing numerous longitudinal, multicenter, interventional and double-blind randomized clinical trials to confirm their efficacy and safety of these therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.